Novavax Stock Earnings Reports

Novavax is executing a strategic shift from being a standalone commercial vaccine company to a capital-efficient partner/technology provider focused on monetizing its Matrix‑M adjuvant via non‑exclusive licenses and material transfer agreements (MTAs). Key operational highlights: multiple MTAs and licensing relationships with large pharma (4 of the top 10) and several smaller biotechs, including a January license with Pfizer (received $30M upfront; up to $250M milestones per product plus long‑term royalties) and significant prior monetization from Sanofi (>$800M to date). The company is prioritizing capital‑efficient R&D, retaining core in‑house capabilities, and advancing a prioritized in‑house C. difficile vaccine toward IND‑enabling studies with a potential clinic entry in 2027 based on encouraging preclinical data (including mucosal IgA and survival endpoints). Financials: Q1 2026 revenue was $140M (down vs. a 2025 quarter that included a large noncash APA recognition), but partner‑related supply sales and licensing/royalty revenue rose >100% YoY. Non‑GAAP combined R&D and SG&A were reduced ~23% YoY; GAAP net loss was $9M for the quarter. Novavax ended Q1 with $818M in cash and receivables, added $80M nondilutive cash (including the Pfizer upfront and a $50M draw on a credit facility), and believes it can fund operations into 2028 without assuming future partner payments. Guidance reiterated: 2026 adjusted total revenue framework $230–$270M (midpoint $250M), non‑GAAP combined R&D & SG&A guidance $310–$340M (2026). Longer‑term cost target refined to $150–$200M non‑GAAP combined R&D & SG&A for 2028. Additional supportive data: Sanofi’s COMPARE Phase IV showed Nuvaxovid had fewer side effects than Moderna’s next‑gen vaccine, which Novavax frames as favorable for partner and end‑user acceptance. Risks remain from execution, partner clinical/commercial success, regulatory approvals, and typical development uncertainties.